Liquidia Technologies (LQDA)
(Delayed Data from NSDQ)
$10.12 USD
+0.19 (1.91%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $10.13 +0.01 (0.10%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
LQDA 10.12 +0.19(1.91%)
Will LQDA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for LQDA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LQDA
Travere (TVTX) Soars 5.9%: Is Further Upside Left in the Stock?
Liquidia Technologies (LQDA) Soars 14.1%: Is Further Upside Left in the Stock?
LQDA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biotech Stock Roundup: CRL for REGN, GILD's Drug Approval, LQDA Down on News
Liquidia (LQDA) Down on FDA Delaying Full Approval for Yutrepia
Liquidia Technologies, Inc. (LQDA) Reports Q2 Loss, Lags Revenue Estimates
Other News for LQDA
Court Finds United Therapeutics? Interference with Launch of Generic Treprostinil Injection Caused Losses of More Than $137 Million
Liquidia says court finds United's interference caused losses over $137M
Caligan Partners LP Bolsters Portfolio with Significant Stake in Liquidia Corp
Liquidia Corporation Announces Raise of $67.5 Million from New Common Stock Financings and $32.5 Million Advance from HealthCare Royalty Under Current Financing Agreement
Liquidia stock rises after it prices public and private offering